vitiligo
Conditions
Interventions
control group:NB-UVB + lipoic acid tablets
control group:NB-UVB + Placebo
Sponsors
The First Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
14 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) age 14-65 years old, inpatient or outpatient, male or female; (2) meet the diagnostic criteria of clinically diagnosed primary sporadic quiescent (resting stage standard, see Annex 2) patients with vitiligo; (3) subjects volunteered to participate, be required to sign an informed consent form; (4) leukoplakia dispersed in three or more anatomical zone, at least a maximum diameter of greater than 2cm, with a total area of> 1% of body surface area.
Exclusion criteria
Exclusion criteria: (1) pregnant and lactating women; (2) serious heart, liver, renal insufficiency; (3) pre-cancerous skin lesions; (4) systemic lupus erythematosus (SLE), dermatomyositis ultraviolet treatment contraindications; (5) diabetes; (6) with immunosuppressive therapy; (7) the eye, vulva, and other parts of skin lesions in patients; Nearly 2 months (8) received glucocorticoid NB-UVB excimer laser treatment, nearly one month to accept any treatment, at the same time to participate in other clinical trials; (9) secondary vitiligo (secondary to discoid lupus erythematosus, chronic eczema, vitiligo); (10) can not adhere to treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lesion change; | — |
Countries
China
Contacts
Public ContactXing-hua Gao
Outcome results
None listed